Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05065957 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05065957 · ClinicalTrials.gov record · last posted 2025-04-30

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

StatusRecruiting
PhasePhase 2/3
Started2022-03-29
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 30, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2021-09-23; most recent amendment 2025-04-28. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-12-22
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05065957
Lead Sponsor InnoPharmax Inc.
Conditions Biliary Tract Cancer
Enrollment 180 participants
Start Date 2022-03-29
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-30